Complimentary access to the JTO and a 15% discount on the publication fees for the newest open-access IASLC journal, JTO CRR. Both JTO and JTO CRR feature novel research about the prevention, detection, diagnosis, and treatment of all thoracic malignancies. JTO is among the top 5% of all oncology journals and the leading journal that is entirely focused on thoracic oncology.
JTO and JTO CRR feature novel research about the prevention, detection, diagnosis, and treatment of all thoracic malignancies. With an Impact Factor of 20.121, JTO is among the top 5% of all oncology journals and the leading journal that is entirely focused on thoracic oncology. It emphasizes a multidisciplinary approach and includes original research, reviews and opinion pieces. JTO CRR, IASLC’s open access companion title, publishes a range of manuscripts from subset analyses of published trials to high-quality case reports. JTO CRR is indexed in PubMed Central.
JTO CRR Editor-in-Chief
Emily Stone, MBBS, PhD, FRACP
Dr. Emily Stone will officially take the reins as the Editor-in-Chief of JTO Clinical and Research Reports (JTO CRR) on January 9, 2023, as Dr. Alex Adjei steps down from the role and continues his role as the Editor-in-Chief of the Journal of Thoracic Oncology (JTO). Dr. Stone is a consultant respiratory physician and Head of Thoracic Medicine within the Department of Thoracic Medicine and Lung Transplantation at St Vincent’s Hospital Sydney. She is the founding and immediate past Chair of the St Vincent’s Hospital Lung Cancer Multidisciplinary Team and the Deputy Board Chair of the Thoracic Oncology Group of Australasia. She has been an Associate Editor for both the JTO and JTO CRR since 2016 and 2020, respectively. She also served as the Chair of the IASLC Tobacco Control Committee from 2018 to 2019. Her chief clinical and research interests are in the fields of lung cancer screening, multidisciplinary team care, and tobacco control.
We are excited for the next chapter under Dr. Stone's editorial leadership and strategic stewardship of JTO CRR. The editorial teams of JTO and JTO CRR are committed to continuing to join forces towards research excellence, impacting clinical practice and global readership. We want to express our utmost appreciation to Dr. Adjei for his leadership and vision in paving the way for JTO CRR. Please join us in welcoming Dr. Stone to the JTO CRR family.
JTO by the Numbers
Recent journal articles
Histone deacetylase 6 inhibition exploits selective metabolic vulnerabilities in LKB1 mutant, KRAS driven non-small cell lung cancer
Poziotinib in Treatment-Naïve Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-label Phase 2 Trial (Cohort 4)
Classification of Tumor Immune Microenvironment (TIME) According to PD-L1 Expression and Immune Infiltration Predicts Response to Immunotherapy plus Chemotherapy in Advanced NSCLC Patients
D-1553 (garsorasib), a Potent and Selective Inhibitor of KRASG12C in Patients with Non-Small Cell Lung Cancer: Phase I Study Results
Primary Resistance to Larotrectinib in a Patient with Squamous Non-Small Cell Lung Cancer with Subclonal NTRK1 Fusion: Case Report
Institution-Level Evolution of Lung Cancer Resection Quality with Implementation of a Lymph Node Specimen Collection Kit.
Exon20-mutated NSCLC: Extending the dataset to allow the recognition of potential causes.
Racial, Ethnic, and Socioeconomic Characteristics Independently Predict for Cachexia Risk and Associated Survival Outcomes in Stage IV Non-Small Cell Lung Cancer: A Brief Report
Discover the JTO
More than 80 international experts compose the JTO Editorial Board, allowing for a quick turn-around time of 5.4 days to initial decision, and an average of 7 days for revisions, a fast track category, publish on acceptance (within 5 days), and promotion of select articles via social media and press releases.
JTO emphasizes a multidisciplinary approach and includes original research (clinical trials and translational or basic research), reviews, and opinion pieces. Authors can take advantage of Elsevier's Researcher Academy, Navigate your research journey with Researcher Academy—free e-learning modules on navigating your career developed by global experts.
JTO reviewers are given the privilege of getting the first look at novel research, phase III data, and potentially practice-changing concepts. Email your CV to email@example.com.